CRANFORD, N.J., Oct. 27, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a
specialty pharmaceutical company developing and commercializing
critical care drug products, announced that it has issued an
October 2020 Letter to Shareholders.
The letter addresses recent updates on the Company's business and
clinical developments and news for its pipeline of products.
Recent highlights include:
- The signing of an exclusive worldwide license agreement with
Novellus Therapeutics, Limited for a cellular therapy to treat
acute respiratory distress syndrome (ARDS), a leading complication
of COVID-19
- Received positive second interim analysis report from the
independent Drug Monitoring Committee (DMC) for the Mino-Lok
pivotal Phase 3 trial
- Submission of a pre-investigational new drug (PIND)
consultation request for Mino-Wrap with written response and
guidance from the FDA expected in November of 2020
- Completed patient survey for Halo-Lido to develop a patient
reported outcome (PRO) instrument with plans set to begin Phase
2b trial in the first quarter of
2021
"While the COVID-19 pandemic has affected patient recruitment in
almost all clinical trials, including our own, I'm proud that the
Company has continued to make significant progress across our
entire pipeline," said Myron
Holubiak, Chief Executive Officer of Citius. "Our focus and
movement with these projects demonstrate the value we're intent on
building for shareholders, and I look forward to sharing more
developments in the future."
To view the Company's Corporate Update Letter in its entirety,
please visit:
https://www.citiuspharma.com/wp-content/uploads/2020/10/CTXR_October-2020_Shareholder-Letter_final.pdf
About Citius Pharmaceuticals, Inc.
Citius is a
late-stage specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives and cancer care. For more information,
please visit www.citiuspharma.com.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "should," and
"may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results
to differ materially from those currently anticipated are: risks
associated with conducting clinical trials and drug development;
our dependence on third-party suppliers; our need for
substantial additional funds; patent and intellectual property
matters; market and other conditions; our ability to attract,
integrate, and retain key personnel; the estimated markets for our
product candidates and the acceptance thereof by any market; risks
related to our growth strategy; risks relating to the results of
research and development activities; uncertainties relating to
preclinical and clinical testing; the early stage of products under
development; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; our ability
to identify, acquire, close and integrate product candidates and
companies successfully and on a timely basis; government
regulation; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-issues-october-2020-letter-to-shareholders-301160421.html
SOURCE Citius Pharmaceuticals, Inc.